Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023

/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...

Related Keywords

Chicago ,Illinois ,United States ,China ,American ,Valerie Malyvanh Jansen ,Yakun Wang ,Corporate Communications Investor Relations ,Elevation Oncology Inc ,Nasdaq ,Group Limited ,Drug Administration ,American Society Of Clinical Oncology ,Prnewswire Elevation Oncology Inc ,Exchange Commission ,American Society ,Clinical Oncology ,Elevation Oncology ,Chief Medical Officer ,Poster Discussion ,Molecularly Targeted Agents ,Session Date ,Discussion Date ,Investigational New Drug ,Private Securities Litigation Reform Act ,Oncology Investor ,Corporate Communications ,